NEW YORK, April 29, 2026
Aidoc has announced the successful completion of a $150 million Series E funding round led by Goldman Sachs, with participation from major investors including General Catalyst, SoftBank Vision Fund 2, and NVentures. This latest investment brings Aidoc’s total funding to over $500 million, underscoring the rapid acceleration of enterprise-scale clinical artificial intelligence adoption across global healthcare systems. The funding will be used to expand Aidoc’s clinical foundation model CARE™ and its aiOS™ enterprise platform, which are designed to deliver earlier, safer, and more accurate diagnoses, addressing one of healthcare’s most pressing challenges—diagnostic errors contributing to hundreds of thousands of deaths annually.
Clinical AI Platform Targets Diagnostic Errors at Scale
Aidoc’s technology is built on its proprietary CARE™ foundation model, a next-generation AI system capable of analyzing multiple imaging modalities and disease conditions simultaneously. Unlike traditional AI tools that focus on single-use cases, CARE™ enables broad, system-wide clinical deployment, allowing hospitals to streamline workflows and improve diagnostic accuracy across departments. The platform is delivered through aiOS™, an enterprise operating system that integrates AI directly into clinical workflows, enabling real-time analysis of imaging data such as CT scans and X-rays.
This approach supports end-to-end automation, from image interpretation to draft report generation, significantly reducing the burden on clinicians while improving speed and precision in decision-making. Currently, Aidoc’s platform analyzes over 60 million patient cases annually and is deployed across nearly 2,000 hospitals worldwide, highlighting its growing impact on global healthcare infrastructure.
Regulatory Milestones Strengthen AI Adoption in Healthcare
Advertisement
A key differentiator for Aidoc is its focus on regulatory rigor and compliance, which is essential for deploying AI solutions in real-world clinical environments. The company recently achieved a landmark FDA clearance for its CARE™ foundation model, marking one of the first approvals for a multi-indication AI triage system in clinical imaging. This milestone reflects Aidoc’s commitment to meeting stringent safety, validation, and performance standards, aligning with Good Clinical Practice (GCP) and medical device regulatory frameworks.
As healthcare systems increasingly adopt AI-driven diagnostic tools, the ability to demonstrate clinical reliability, transparency, and governance becomes critical. Aidoc’s success in this area positions it as a trusted leader in regulated clinical AI, capable of scaling solutions across complex healthcare networks while maintaining patient safety and data integrity.
Funding Accelerates Global Expansion and Innovation
The newly secured capital will enable Aidoc to expand its clinical AI capabilities, including broader disease coverage, enhanced imaging analysis, and the development of automated reporting tools that support full-cycle clinical workflows. Additionally, the funding will drive global deployment of the aiOS™ platform, helping healthcare providers transition from fragmented AI tools to centralized, enterprise-level solutions. This shift is critical as hospitals seek to optimize efficiency, reduce costs, and improve patient outcomes in increasingly complex care environments.
From a GxP perspective, Aidoc’s platform demonstrates strong alignment with quality management and regulatory compliance standards, ensuring scalability without compromising clinical safety or operational reliability. As the demand for AI-driven healthcare solutions continues to rise, Aidoc’s latest funding round reinforces its role in shaping the future of precision diagnostics, enabling healthcare systems to deliver faster, safer, and more effective patient care on a global scale.
Source: Aidoc press release
